Functional Mushroom Gummie Founder Struggles to Balance Stress and Growth
After battling chronic gut issues since childhood and cycling through a bunch of traditional medicine, Schaper found relief through functional mushrooms and never looked back. She teamed up with a co-founder to create SuperMush, a line of sugar-free mushroom-based gummies, mints, and mouth sprays that promote energy, focus, and relaxation.
But as the company has grown, so has the stress. "The irony is we're creating a mental health brand," Schaper said, "and the attempt to maintain our own mental health through the process of building and scaling a CPG company is pretty wild."
Schaper recently appeared on Entrepreneur Therapy, presented by Amazon Business, to talk with Dr. Drew and Kim Perell about what keeps her up at night—and how to protect her peace while scaling a wellness brand in a highly competitive space.
Related: The Wellness Industry Is Now Richer Than Big Pharma and Sports
The first problem? Finding balance between the creative side she loves and the operational demands of a startup trying to grow fast. "We've now had to shift completely into like operations spreadsheet mode," she said. "It's been dominating our time."
Perell suggested that it might be time to consider hiring someone whose strength is in backend operations. "That person will be a game changer in your business," she told Schaper. "It may mean giving something up, but it will allow you to do your best work."
Dr. Drew honed in on Schaper's stress level. "You gloss it over with that beautiful smile," he told her, "but it's going to catch up with you." He encouraged her to find a real way to relieve the pressure—whether that's boxing, therapy, or talking to a close friend.
Schaper agreed that the emotional ups and downs of entrepreneurship can be discouraging, especially when the grind doesn't always lead to immediate results. "I could work 80 hours a week and get zero investment checks," she said. "Then the next week, I work three hours and get a million dollars."
But she left the session with a new perspective. "I love what they shared," she said. "And I have some good, clear takeaways."
Entrepreneur Therapy is presented by Amazon Business. Smart business buying starts with Amazon Business. Learn more.
Related: 'You Need Support:' Honest Advice for a Founder Trying to Do It All Alone
Related:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Roper Tech Lifts 2025 Outlook As AI, Acquisitions Fuel Double-Digit Growth
Roper Technologies (NASDAQ:ROP) reported second-quarter results Monday. It clocked quarterly adjusted earnings per share of $4.87, beating the street view of $4.83. Quarterly sales of $1.94 billion outpaced the analyst consensus estimate of $1.92 billion. Revenue increased by 13% year over year, with a 7% contribution from acquisitions and a 6% increase in organic company exited the quarter with cash and equivalents worth $242.4 million and net inventories worth $132.2 million. Roper Technologies' long-term debt (net of the current portion) as of quarter end was $7.9 billion, higher than $6.6 billion as of June 30, 2025. View more earnings on ROP Roper Technologies CEO Neil Hunn said the company delivered strong execution in the second quarter while continuing to innovate and invest for long-term growth. He highlighted AI as a key driver, enhancing solutions and unlocking new opportunities across the portfolio. Hunn noted that growth remained balanced across all three segments, setting the stage for a strong second half of the year. Outlook Roper Technologies expects fiscal 2025 adjusted earnings per share of $19.90-$20.05 (up from the prior $19.80-$20.05), versus the $19.92 analyst consensus estimate. It also raised its full-year total revenue growth outlook to ~13% or $7.95 billion (compared to a previous outlook of ~12% or $7.88 billion and an analyst consensus estimate of $7.86 billion). It reiterated organic revenue growth of +6-7%. The company anticipates adjusted EPS of $5.08-$5.12 for the third quarter, compared to the $5.08 analyst consensus estimate. Price Action: ROP stock is up by 0.42% to $547.11 at last check Monday. Photo by IgorGolovniov via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? ROPER TECHNOLOGIES (ROP): Free Stock Analysis Report This article Roper Tech Lifts 2025 Outlook As AI, Acquisitions Fuel Double-Digit Growth originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
Corn Giving Back All of Friday's Gains on Monday
Corn futures are down roughly 7 cents per bushel across most delivery months this morning. Futures closed 6 to 7 cents higher on Friday, so this is a 'fade' after failing to close a chart gap from the July 4th weekend. Preliminary open interest on Friday was up 10,834 contracts, indicating the short covering was limited, with some fresh longs. The CmdtyView national average new crop Cash Corn price this morning is $3.78. Commitment of Traders data showed managed money covering some shorts in the week ending on July 15, with their net short down 29,106 contracts to 174,755 contracts. Commercials added 10,113 contracts to their net short position to 40,294 contracts. More News from Barchart What is Watson Watching in the Grains Sector this Week? Soybean Meal Prices Are Rebounding. How Much Higher Can They Go? Brazil Coffee Harvest Pressures Hammer Prices Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. This morning's USDA Grain Inspections report indicated 983,625 MT were inspected for export in the reporting week ending July 17. That was down slightly from 991,257 MT a year ag0, and well off of the updated 1.314 MMT shipped the previous week. The YTD inspections total 58.718 MMT (~2.315 billion bushels), up 28.9% from a year ago at the same time. Sep 25 Corn is at $4.01, down 7 1/2 cents, Nearby Cash is at $3.87 1/4, down 7 1/2 cents, Dec 25 Corn is at $4.20 1/2, down 7 1/4 cents, Mar 26 Corn is at $4.37 3/4, down 7 cents, New Crop Cash is at $3.78 3/4, down 7 1/4 cents, On the date of publication, Austin Schroeder did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Why Globus Medical (GMED) Shares Are Trading Lower Today
What Happened? Shares of medical device company Globus Medical (NYSE:GMED) fell 6.6% in the afternoon session after the unexpected resignation of its President and CEO, Daniel Scavilla. The medical device company announced that Scavilla resigned effective July 18 to pursue another opportunity. He will be replaced by Keith Pfeil, who was promoted from his role as Chief Operating Officer and Chief Financial Officer. While the company reaffirmed its full-year 2025 guidance for revenue and earnings per share, the sudden change in the corner office appears to have unsettled investors, leading to the stock's decline. The departure introduces a level of uncertainty, even with a well-regarded internal successor and positive sales momentum. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Globus Medical? Access our full analysis report here, it's free. What Is The Market Telling Us Globus Medical's shares are not very volatile and have only had 7 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 2 months ago when the stock gained 5.8% on the news that the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cut U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains. However, President Trump clarified that tariffs could go "substantially higher" if a full deal with China wasn't reached during the 90-day pause, but not all the way back to the previous levels. Still, the agreement cooled fears of a prolonged trade war, helped stabilize expectations for global growth and trade flows and fueled renewed optimism. The optimism appeared concentrated in key trade-sensitive sectors, particularly technology, retail, and industrials, as lower tariffs reduce cost pressures and restore cross-border demand. Globus Medical is down 35.6% since the beginning of the year, and at $52.69 per share, it is trading 43.5% below its 52-week high of $93.32 from January 2025. Investors who bought $1,000 worth of Globus Medical's shares 5 years ago would now be looking at an investment worth $1,102. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Sign in to access your portfolio
